Latest News & Features
Americas
A US appeals court has handed the generic drugmaker victory in a closely watched dispute over a treatment for a serious inherited kidney condition, dealing a setback to its branded rival. 22 May 2026
Americas
How can innovators secure reliable protection across diagnostics, genetics, and AI-integrated devices while navigating Section 101 and 112 pitfalls? This comprehensive panel addresses strategies to clear fundamental patentability hurdles amid shifting court decisions and USPTO guidelines. 22 May 2026
Americas
European officials have again sided with Glenmark, concluding that the 3D mark for Boehringer’s HandiHaler device is ineligible for registration. 21 May 2026
Europe
The court has imposed a financial penalty after finding it continued promoting banned devices online despite an injunction covering five European countries. 21 May 2026
Americas
The rapid evolution of CRISPR and base editing brings transformative medical potential alongside deeply complex IP and licensing hurdles. This session explores how companies can balance innovation with risk mitigation in a crowded and highly contested precision medicine landscape. 21 May 2026
Asia
Backed by the country’s wider AI ambitions, Google has signed a deal to roll out healthcare, scientific research, and safety initiatives. 20 May 2026
Americas
The firm brings in a former VP at a biotech company, with biologics experience across antibodies, antibody drug-conjugates, peptides and gene and cell therapies. 20 May 2026
Americas
The influx of biosimilars and generics requires innovator companies and challengers alike to continually refine their litigation tactics. This panel dissects current trends in Hatch-Waxman and BPCIA frameworks, providing a roadmap for defending franchises and navigating market entry. 20 May 2026
Americas
In the firm’s second IP conflict dispute in a year, a healthcare tech company claims Kirkland lawyers "committed the cardinal sin of trying to represent the conflicting interests of opposing parties". 19 May 2026
Americas
The award could rise to several billions under federal antitrust law, after the pharma company was found to have engaged in anticompetitive conduct over constipation drug Amitiza. 19 May 2026